LONDON (Reuters) - The cost of specialty biotech drugs increased 8.7 percent last year in the United States, three times the rate of inflation, according to AARP, a Washington-based group representing the elderly.
LONDON (Reuters) - The cost of specialty biotech drugs increased 8.7 percent last year in the United States, three times the rate of inflation, according to AARP, a Washington-based group representing the elderly.
